157 related articles for article (PubMed ID: 27311576)
21. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.
Ali A; Aydin C; Gildemeister R; Romano KP; Cao H; Ozen A; Soumana D; Newton A; Petropoulos CJ; Huang W; Schiffer CA
ACS Chem Biol; 2013 Jul; 8(7):1469-78. PubMed ID: 23594083
[TBL] [Abstract][Full Text] [Related]
22. Resistance mutations against HCV protease inhibitors and antiviral drug design.
Shang L; Lin K; Yin Z
Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from
Patil VS; Harish DR; Vetrivel U; Roy S; Deshpande SH; Hegde HV
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164341
[No Abstract] [Full Text] [Related]
24. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Franco S; Clotet B; Martínez MA
Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
[TBL] [Abstract][Full Text] [Related]
25. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
26. Unraveling the mechanisms of Sofosbuvir resistance in HCV NS3/4A protease: Structural and molecular simulation-based insights.
Shahab M; Khan A; Khan SA; Zheng G
Int J Biol Macromol; 2024 May; 267(Pt 2):131629. PubMed ID: 38631585
[TBL] [Abstract][Full Text] [Related]
27. Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies.
Wadood A; Riaz M; Jamal SB; Shah M
Mol Biol Rep; 2014 Jan; 41(1):337-45. PubMed ID: 24234753
[TBL] [Abstract][Full Text] [Related]
28. Antiviral phytochemicals identification from Azadirachta indica leaves against HCV NS3 protease: an in silico approach.
Ashfaq UA; Jalil A; Ul Qamar MT
Nat Prod Res; 2016 Aug; 30(16):1866-9. PubMed ID: 26274064
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
Zhou Y; Müh U; Hanzelka BL; Bartels DJ; Wei Y; Rao BG; Brennan DL; Tigges AM; Swenson L; Kwong AD; Lin C
J Biol Chem; 2007 Aug; 282(31):22619-28. PubMed ID: 17556358
[TBL] [Abstract][Full Text] [Related]
30. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
[TBL] [Abstract][Full Text] [Related]
31. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations.
Ren J; Vaid TM; Lee H; Ojeda I; Johnson ME
J Comput Aided Mol Des; 2023 Jan; 37(1):53-65. PubMed ID: 36427108
[TBL] [Abstract][Full Text] [Related]
33. A 3D structural model and dynamics of hepatitis C virus NS3/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity.
Rimmert B; Sabet S; Ackad E; Yousef MS
J Biomol Struct Dyn; 2014; 32(6):950-8. PubMed ID: 23768174
[TBL] [Abstract][Full Text] [Related]
34. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
Belfrage AK; Abdurakhmanov E; Kerblom E; Brandt P; Oshalim A; Gising J; Skogh A; Neyts J; Danielson UH; Sandström A
Bioorg Med Chem; 2016 Jun; 24(12):2603-20. PubMed ID: 27160057
[TBL] [Abstract][Full Text] [Related]
35. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
Venkatraman S
Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
37. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
Wadood A; Riaz M; Uddin R; Ul-Haq Z
PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230
[TBL] [Abstract][Full Text] [Related]
38. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
39. Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients.
Dvory-Sobol H; Wong KA; Ku KS; Bae A; Lawitz EJ; Pang PS; Harris J; Miller MD; Mo H
Antimicrob Agents Chemother; 2012 Oct; 56(10):5289-95. PubMed ID: 22869562
[TBL] [Abstract][Full Text] [Related]
40. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
